NEOGENOMICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.18 USD | -1.46% |
|
+0.17% | -6.33% |
| May. 02 | North American Morning Briefing : Stock Futures -3- | DJ |
| Apr. 30 | Needham Lowers Price Target on NeoGenomics to $19 From $24 Due to Peer Multiple Compression, Maintains Buy Rating | MT |
Presentation Operator MessageOperator (Operator)Welcome to the NeoGenomics First Quarter 2024 ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
NeoGenomics, Inc. provides a range of oncology diagnostic testing and consultative services which includes technical laboratory services. The Company offers professional interpretation of laboratory test results by licensed physicians who specialize in pathology and oncology. Its segments include Clinical Services and Advanced Diagnostics. The Clinical Services segment consists of clinical cancer testing; interpretation and consultative services; molecular and NGS testing, and comprehensive technical and professional services offering. Its Clinical Services customers include community-based pathology and oncology practices, hospital pathology labs, reference labs, and academic centers. The Advanced Diagnostics segment consist of clinical trials and research, validation laboratory services, and informatics. Its Advanced Diagnostics customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials.
Calendar
2024-05-23
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
15.4
USD
Average target price
20.45
USD
Spread / Average Target
+32.82%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.33% | 1.97B | |
| -16.80% | 8.79B | |
| +65.95% | 4.19B | |
| -4.03% | 2.48B | |
| -42.54% | 2.29B | |
| -19.90% | 1.56B | |
| -41.24% | 1.22B | |
| +10.26% | 1.13B | |
| +18.74% | 933M | |
| -10.93% | 910M |
- Stock Market
- Equities
- NEO Stock
- News NeoGenomics, Inc.
- Transcript : NeoGenomics, Inc., Q1 2024 Earnings Call, Apr 30, 2024
